RxDoctor Payments Data

Vincent Ortolano, MD

Urology · Albuquerque, NMNPI 1669497814

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Boston Scientific at 52.7% of the total. Reporting peaked in 2020 at $663 and has fallen 96.6% since, to $23 in 2025. That places this record below the midpoint for urology clinicians in NM, where the typical reported total is $1,519.

$1,420in general payments, 2019–2025

Across 29 payments — averaging $48.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$749
  • Astellas Pharma US Inc$351
  • Johnson & Johnson$114
  • Bayer$57
  • Pfizer$43
  • RGH Enterprises LLC$25
  • plus $81 from 5 others

What the payments were for

  • Travel & lodging$55139%
  • Food & beverage$80957%
  • Education$604%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,420 in reported general payments places this provider in the 45th percentile of 46 urology providers in New Mexico.

See all urology providers in New Mexico

Medicare billing

Part B allowed, 2024
$2,996
Medicare patients
13
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate12$84,366
MyrbetriqMirabegron40$33,262
Tamsulosin Hcl187$3,504
Potassium Citrate ErPotassium Citrate26$2,403
Finasteride96$1,886
Bicalutamide30$1,002
NitrofurantoinNitrofurantoin Macrocrystal37$968
Doxazosin Mesylate44$678
Oxybutynin Chloride ErOxybutynin Chloride15$164
Ciprofloxacin Hcl11$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$351$33,26240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 46 urology providers in New Mexico.

Other urology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →